Journal Article |
| K.C. Biju, Rene A. Santacruza, Cang Chen, Qing Zhou, Jiemin Yao, Sara L. Rohrabaugh, Robert A. Clark, James L. Roberts, Kimberley A. Phillips and Senlin Li. Bone marrow-derived microglia based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinsons disease Neurosci Lett 2013 Feb;535:24-29.
|
| Xiao, W., Peng, Y., Liu, Y., Li, Z., Li, S., Zheng, X. HSCARG Inhibits NADPH Oxidase Activity through Regulation of the Expression of p47phox PLoS ONE 2013 Jan;8.
|
| A-Gonzalez, N., Guilln, J.A. , Gallardo, G., Diaz, M., de la Rosa, J.V., Hernndez, I.H., Casanova-Acebes, M., Lopez, F., Tabraue, C., Beceiro, S., Hong, C., Lara, P.C., Andujar, M., Arai, S., Miyazaki, T., Li, S., ngel L. Corb, A.L., Tontonoz, P., Hidalgo A., and Castrillo A. The Nuclear Receptor LXR controls the functional specialization of splenic macrophages, Accepted for publication Nature Immunology 2013 Jan;.
|
| Li, X., Redus, L., Chen, C., Martinez, P.A., Strong, R., Li S. (correspondent author), Oconnor, J. Impaired spatial learning precedes the onset of motor symptoms in the MitoPark mouse model of Parkinsons Disease, [PONE-D-13-11675], In revision PLoS ONE 2013 Jan;.
|
| Imam, S., Binienda, Z., Paule, M., Slikker, W., Clark, R. A., Li, S., Ali, S. Neuroprotective efficacy of a new brain-penetrating c-Abl inhibitor in a murine Parkinsons disease model, Accept for publication [PONE-D-13-03294R2] PLoS ONE 2013 Jan;.
|
| M C Levin, U Lidberg, P Jirholt, M Adiels, A Wramstedt, K Gustafsson, D R Greaves, S Li, S Fazio, M F Linton, S-O Olofsson, J Born, and I Gjertsson. Evaluation of macrophage-specific promoters using lentiviral delivery in mice Gene Therapy 2012 Jan;19:1041-1047.
|
| Guiming Li, Biju Chandu, Xianmin Xu, Anthony J. Valente, Robert L. Reddick, Gregory L. Freeman, Seema S. Ahuja, Robert A. Clark, and Senlin Li. Macrophage LXRa gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR-/- mice Gene Therapy 2011 Jan;18(8):835-841.
|
| Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, Li S. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinsons disease J Neurosci 2011 Jan;31(1):157-163.
|
| Biju KC, Zhou Q, Li Q, Imam S, Roberts JL, Morgan WW, Clark RA, and Li S. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: A therapeutic strategy for Parkinsons disease Molecular Therapy 2010 Jan;18:1536-1544.
|
| Valente AJ, Zhou Q, Lu Z, He W, Qiang M, Ma W, Li G, Wang L, Banfi B, Steger K, Krause KH, Clark RA, Li S. Regulation of NOX1 expression by GATA, HNF-1alpha, and Cdx transcription factors Free Radic Biol Med 2008 Feb;44(3):430-443.
|
Abstract |
| Biju K.C, Qing Zhou, Guiming Li, Syed Imam, James L Roberts, William W Morgan, Robert A Clark, and Senlin Li. Development of a Hematopoietic Stem Cell-Based Gene Therapy for Parkinsons Disease in the MPTP Mouse Model; 2008 May. (Research Day, Department of Medicine, UTHSCSA).
|
Federal |
| Funding Agency |
NIH |
| Title |
Influence of High Glucose on Endothelial Function |
| Status |
Active |
| Period |
8/2012 - 7/2017 |
| Role |
Co-Investigator |
| Grant Detail |
|
| Funding Agency |
NIH |
| Title |
CSF-1 in Dental Biology |
| Status |
Active |
| Period |
7/2008 - 6/2013 |
| Role |
Co-Investigator |
| Grant Detail |
This proposal is to study the hypotheses: 1) cell-specific cis-acting elements in the -774 bp CSF-1 promoter direct gene expression inameloblast lineage cells during tooth development, 2) CSF-1 isoforms differentially regulate enamelmatrix and root formation and result in distinct phenotypes, and 3) lentiviral-mediated gene deliveryof sCSF-1 to ameloblasts will rescue enamel/root defects in op/opS mice. CSF-1 is the growth factor for cells of the monocyte-macrophage lineage. |
| Funding Agency |
IIMS |
| Title |
Preclinical study of a neuroprotective therapy for Parkinsons disease in non-human primate |
| Status |
Active |
| Period |
6/2011 - 5/2013 |
| Role |
Principal Investigator |
| Grant Detail |
|
| Funding Agency |
Veterans Administration |
| Title |
Macrophage-mediated Gene Therapy of Atherosclerosis2 |
| Status |
Active |
| Period |
1/2009 - 12/2012 |
| Role |
Principal Investigator |
| Grant Detail |
The major goals of this proposal are to develop novel therapy for atherosclerosis by knocking down detrimental gene (such as PPAR delta) expression in macrophages using our macrophage-specific promoters combined with lentiviral transduction and hematopoietic stem cell transplantation. |
| Funding Agency |
Veterans Administration |
| Title |
Use of Novel Transgenic/Knockout Mouse Models to Identify Environmental Hazards, Genetic Deficiencies, and Therapies that Play a Role in the Etiology of Neurodegenerative Diseases |
| Status |
Active |
| Period |
4/2005 - 12/2011 |
| Role |
Contributor |
| Grant Detail |
The research focus of our REAP is to use novel transgenic/knockout mouse models to identify environmental hazards, genetic deficiencies, and therapies that play a role in the etiology of neurodegenerative diseases of importance to veterans and to use the data obtained with animal models to study potential mechanisms of neurodegeneration in human subjects . The first goal of the REAP is to provide a structure that allows investigators to focus their efforts on a common theme: identifying common mechanisms in the major neurodegenerative diseases. For example, the REAP will provide VA investigators with common research tools, animal models, and Core facilities. Thus, the research emanating from the REAP will be greater than the sum of the research generated by individual researchers in the absence of the REAP. A second goal of the REAP will be to provide an outstanding environment for the training of the next generation of VA medical research investigators. At the end of five years, we envision that 8 to 10 postdoctoral fellows will have been trained through our REAP. |
| Funding Agency |
NIH / NINDS |
| Title |
Macrophage Gene Therapy of Neurodegenerative Diseases |
| Status |
Complete |
| Period |
7/2004 - 6/2010 |
| Role |
Principal Investigator |
| Grant Detail |
The goal of this project is to develop gene therapy strategies for neurodegenerative diseases using ex vivo transduction of hematopoietic stem cells with lentiviral vectors expressing therapeutic genes driven by highly active macrophage-selective synthetic promoters. |
Private |
| Funding Agency |
WILLIAM & ELLA OWENS MED RSCH FOUNDATION |
| Title |
Development of a novel disease-modifying therapy for Parkinsons patients |
| Status |
Active |
| Period |
1/2013 - 12/2013 |
| Role |
Principal Investigator |
| Grant Detail |
|
| Funding Agency |
MICHAEL J. FOX FOUNDATION FOR PARKINSON'' |
| Title |
NOVEL CELL-BASED STRATEGY FOR GDNF DELIVERY IN PARKINSON |
| Status |
Active |
| Period |
12/2012 - 12/2013 |
| Role |
Principal Investigator |
| Grant Detail |
|
| Funding Agency |
AMERICAN HEALTH ASSISTANCE FOUNDATION |
| Title |
iPS-derived microglia-based gene therapy for Alzheimers |
| Status |
Active |
| Period |
7/2011 - 6/2013 |
| Role |
Consultant |
| Grant Detail |
|
| Funding Agency |
Southwest National Primate Research Center (SNPRC) |
| Title |
Preliminary study toward establishing marmoset models for Parkinsons disease |
| Status |
Active |
| Period |
3/2011 - 2/2012 |
| Role |
Principal Investigator |
| Grant Detail |
|
|
| Funding Agency |
IIMS |
| Title |
TRANSLATIONAL TECHNOLOGY RESOURCE SUPPLEMENT |
| Status |
Active |
| Period |
6/2012 - 5/2013 |
| Role |
Principal Investigator |
| Grant Detail |
|